TY - JOUR
T1 - Identification of immunodominant epitopes in envelope glycoprotein of human T Lymphotropic virus type II
AU - Lal, Renu B.
AU - Rudolph, Donna L.
AU - Kaplan, Jonathan E.
AU - Hjelle, Brian
AU - Levine, Paul H.
AU - Coligan, John E.
AU - Viscidii, Raphael P.
PY - 1992/1
Y1 - 1992/1
N2 - A series of synthetic peptides derived from the envelope glycoprotein of human T lymphotropic virus type II (HTLV-II) was used in an enzyme immunoassay to determine the immunodominant epitopes of envelope glycoprotein. Of the 11 synthetic peptides spanning the external glycoprotein of HTLV-II (gp52) and the 3 from the transmembrane protein (gp21), 3 peptides from gp52 (termed Env-2085-102. Env-20-209, and Env-20173-256) reacted with most of the polymerase chain reaction-confirmed HTLV-II specimens (83, 95, and 76%, respectively); all other peptides reacted minimally with these specimens. Env-20173-209 reacted with a greater percentage (91 to 100%) of specimens from different risk groups, including intravenous drug users (n = 30), North American Indians (n = 13), Guaymi Indians from Panama (n = 22), and routine U.S. blood donors (n = 34), when compared with Env-2085-102 (73 to 100%) or Env-203219-256 (68 to 83%). Furthermore, Env-2085-102 and Env-202172-209 had some reactivity (8-25%) with serafrom HTLV-I-infected individuals, whereas Env-20219-256 reacted with 58% of HTLV-I specimens. We conclude that peptides Env-2085-102 and Env-202173-209 represent the type-specific immunodominant epitopes of HTLV-II external glycoprotein.
AB - A series of synthetic peptides derived from the envelope glycoprotein of human T lymphotropic virus type II (HTLV-II) was used in an enzyme immunoassay to determine the immunodominant epitopes of envelope glycoprotein. Of the 11 synthetic peptides spanning the external glycoprotein of HTLV-II (gp52) and the 3 from the transmembrane protein (gp21), 3 peptides from gp52 (termed Env-2085-102. Env-20-209, and Env-20173-256) reacted with most of the polymerase chain reaction-confirmed HTLV-II specimens (83, 95, and 76%, respectively); all other peptides reacted minimally with these specimens. Env-20173-209 reacted with a greater percentage (91 to 100%) of specimens from different risk groups, including intravenous drug users (n = 30), North American Indians (n = 13), Guaymi Indians from Panama (n = 22), and routine U.S. blood donors (n = 34), when compared with Env-2085-102 (73 to 100%) or Env-203219-256 (68 to 83%). Furthermore, Env-2085-102 and Env-202172-209 had some reactivity (8-25%) with serafrom HTLV-I-infected individuals, whereas Env-20219-256 reacted with 58% of HTLV-I specimens. We conclude that peptides Env-2085-102 and Env-202173-209 represent the type-specific immunodominant epitopes of HTLV-II external glycoprotein.
UR - http://www.scopus.com/inward/record.url?scp=0026537115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026537115&partnerID=8YFLogxK
U2 - 10.1016/0042-6822(92)90081-Y
DO - 10.1016/0042-6822(92)90081-Y
M3 - Article
C2 - 1727602
AN - SCOPUS:0026537115
SN - 0042-6822
VL - 186
SP - 274
EP - 279
JO - Virology
JF - Virology
IS - 1
ER -